CTSW represented Suneva Medical, a privately-held aesthetics company, with its acquisition from Spear Pharmaceuticals of worldwide rights to Refissa® and its marketed generic equivalent. Refissa® is a new formulation of tretinoin, a derivative of vitamin A, and effective in the treatment of fine facial wrinkles, tactile roughness of the skin, as well as irregular pigmentation from the sun.
CTSW prepared and negotiated acquisition documents, provided due diligence and regulatory advice and aided in all aspects of the transaction, which Suneva has announced it believes will be “a transformational event for the Company.”